{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:06:23Z","timestamp":1788962783223,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Genet"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Skeletal muscle channelopathies are genetic disorders associated with variants in genes encoding ion channels and related proteins expressed in skeletal muscle. Most commonly, these involve genes encoding voltage-gated ion channels (VGICs) that regulate sarcolemmal excitability, including <jats:italic>CLCN1<\/jats:italic> for ClC-1, <jats:italic>SCN4A<\/jats:italic> for the Nav1.4 \u03b1 subunit, <jats:italic>CACNA1S<\/jats:italic> for the Cav1.1 \u03b1 subunit, and <jats:italic>KCNJ2<\/jats:italic> for Kir2.1. Skeletal muscle channelopathies primarily manifest with two clinical symptoms: myotonia, characterized by delayed muscle relaxation, and paralysis and classified into two disease types: non-dystrophic myotonia and periodic paralysis. Recent advances in the clinical application of next-generation sequencing have improved diagnostic rate and provided epidemiological evidence of the diseases. Furthermore, atypical phenotypes have been identified, indicating that skeletal muscle channelopathies present a broad clinical spectrum. This review provides an updated overview of the clinical and genetic aspects of skeletal muscle channelopathies and discusses key issues that require further investigation.<\/jats:p>","DOI":"10.1038\/s10038-025-01370-w","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T10:15:33Z","timestamp":1754475333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular genetics of skeletal muscle channelopathies"],"prefix":"10.1038","author":[{"given":"Tomoya","family":"Kubota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-5012","authenticated-orcid":false,"given":"Masanori P.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"1370_CR1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/j.2040-4603.2015.tb00630.x","volume":"5","author":"SC Cannon","year":"2015","unstructured":"Cannon SC. Channelopathies of skeletal muscle excitability. Compr Physiol. 2015;5:761\u201390.","journal-title":"Compr Physiol"},{"key":"1370_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/brain\/awp294","volume":"133","author":"E Matthews","year":"2010","unstructured":"Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, et al. The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain. 2010;133:9\u201322.","journal-title":"Brain"},{"key":"1370_CR3","doi-asserted-by":"crossref","unstructured":"Jacobsen LN, Stemmerik MG, Skriver SV, Pedersen JJ, L\u00f8kken N, Vissing J. Contractile properties and magnetic resonance imaging-assessed fat replacement of muscles in myotonia congenita. Eur J Neurol. 2024;31:e16207.","DOI":"10.1111\/ene.16207"},{"key":"1370_CR4","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1007\/s00415-020-10328-1","volume":"268","author":"N Vereb","year":"2021","unstructured":"Vereb N, Montagnese F, Gl\u00e4ser D, Schoser B. Non-dystrophic myotonias: clinical and mutation spectrum of 70 German patients. J Neurol. 2021;268:1708\u201320.","journal-title":"J Neurol"},{"key":"1370_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1113\/jphysiol.1993.sp019843","volume":"470","author":"H Lerche","year":"1993","unstructured":"Lerche H, Heine R, Pika U, George AL, Mitrovic N, Browatzki M, et al. Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III-IV linker. J Physiol. 1993;470:13\u201322.","journal-title":"J Physiol"},{"key":"1370_CR6","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S0140-6736(18)30021-7","volume":"391","author":"R M\u00e4nnikk\u00f6","year":"2018","unstructured":"M\u00e4nnikk\u00f6 R, Wong L, Tester DJ, Thor MG, Sud R, Kullmann DM, et al. Dysfunction of NaV1.4, a skeletal muscle voltage-gated sodium channel, in sudden infant death syndrome: a case-control study. Lancet. 2018;391:1483\u201392.","journal-title":"Lancet"},{"key":"1370_CR7","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/mus.26009","volume":"57","author":"JM Statland","year":"2018","unstructured":"Statland JM, Fontaine B, Hanna MG, Johnson NE, Kissel JT, Sansone VA, et al. Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle Nerve. 2018;57:522\u201330.","journal-title":"Muscle Nerve"},{"key":"1370_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/mus.27947","volume":"68","author":"V Vivekanandam","year":"2023","unstructured":"Vivekanandam V, Seutterlin K, Matthews E, Thornton J, Jayaseelan D, Shah S, et al. Muscle MRI in periodic paralysis shows myopathy is common and correlates with intramuscular fat accumulation. Muscle Nerve. 2023;68:439\u201350.","journal-title":"Muscle Nerve"},{"key":"1370_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000200211","volume":"10","author":"S Holm-Yildiz","year":"2024","unstructured":"Holm-Yildiz S, Krag T, Dysgaard T, Pedersen BS, Witting N, Kodal LS, et al. Quantitative Muscle MRI to Monitor Disease Progression in Hypokalemic Period Paralysis. Neurol Genet. 2024;10:e200211.","journal-title":"Neurol Genet"},{"key":"1370_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/mus.28330","volume":"71","author":"S Holm-Yildiz","year":"2025","unstructured":"Holm-Yildiz S, Krag T, Dysgaard T, Pedersen BS, Witting N, Kodal LS, et al. Muscle Contractility in Hypokalemic Periodic Paralysis. Muscle Nerve. 2025;71:360\u20137.","journal-title":"Muscle Nerve"},{"key":"1370_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34750-8","volume":"8","author":"Y Kokunai","year":"2018","unstructured":"Kokunai Y, Dalle C, Vicart S, Sternberg D, Pouliot V, Bendahhou S, et al. A204E mutation in Nav1.4 DIS3 exerts gain- and loss-of-function effects that lead to periodic paralysis combining hyper- with hypo-kalaemic signs. Sci Rep. 2018;8:16681.","journal-title":"Sci Rep"},{"key":"1370_CR12","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1093\/brain\/awu292","volume":"137","author":"S Corrochano","year":"2014","unstructured":"Corrochano S, M\u00e4nnikk\u00f6 R, Joyce PI, McGoldrick P, Wettstein J, Lassi G, et al. Novel mutations in human and mouse SCN4A implicate AMPK in myotonia and periodic paralysis. Brain. 2014;137:3171\u201385.","journal-title":"Brain"},{"key":"1370_CR13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1212\/01.WNL.0000086820.54065.A0","volume":"61","author":"Y Sugiura","year":"2003","unstructured":"Sugiura Y, Makita N, Li L, Noble PJ, Kimura J, Kumagai Y, et al. Cold induces shifts of voltage dependence in mutant SCN4A, causing hypokalemic periodic paralysis. Neurology. 2003;61:914\u20138.","journal-title":"Neurology"},{"key":"1370_CR14","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1212\/01.WNL.0000145768.09934.EC","volume":"63","author":"S Vicart","year":"2004","unstructured":"Vicart S, Sternberg D, Fournier E, Ochsner F, Laforet P, Kuntzer T, et al. New mutations of SCN4A cause a potassium-sensitive normokalemic periodic paralysis. Neurology. 2004;63:2120\u20137.","journal-title":"Neurology"},{"key":"1370_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/brain\/awh639","volume":"129","author":"SL Venance","year":"2006","unstructured":"Venance SL, Cannon SC, Fialho D, Fontaine B, Hanna MG, Ptacek LJ, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain. 2006;129:8\u201317.","journal-title":"Brain"},{"key":"1370_CR16","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/brain\/awab445","volume":"145","author":"V Vivekanandam","year":"2022","unstructured":"Vivekanandam V, M\u00e4nnikk\u00f6 R, Skorupinska I, Germain L, Gray B, Wedderburn S, et al. Andersen-Tawil syndrome: deep phenotyping reveals significant cardiac and neuromuscular morbidity. Brain. 2022;145:2108\u201320.","journal-title":"Brain"},{"key":"1370_CR17","doi-asserted-by":"crossref","unstructured":"Kokunai Y, Nakata T, Furuta M, Sakata S, Kimura H, Aiba T, et al. A Kir3.4 mutation causes Andersen-Tawil syndrome by an inhibitory effect on Kir2.1. Neurology. 2014;82:1058\u201364.","DOI":"10.1212\/WNL.0000000000000239"},{"key":"1370_CR18","doi-asserted-by":"crossref","unstructured":"Hiraide T, Fukumura S, Yamamoto A, Nakashima M, Saitsu H. Familial periodic paralysis associated with a rare KCNJ5 variant that supposed to have incomplete penetrance. Brain Dev. 2020;43:470\u20134.","DOI":"10.1016\/j.braindev.2020.10.010"},{"key":"1370_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nrendo.2011.58","volume":"7","author":"RMB Maciel","year":"2011","unstructured":"Maciel RMB, Lindsey SC, Dias da Silva MR. Novel etiopathophysiological aspects of thyrotoxic periodic paralysis. Nat Rev Endocrinol. 2011;7:657\u201367.","journal-title":"Nat Rev Endocrinol"},{"key":"1370_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cell.2009.12.024","volume":"140","author":"DP Ryan","year":"2010","unstructured":"Ryan DP, da Silva MRD, Soong TW, Fontaine B, Donaldson MR, Kung AWC, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell. 2010;140:88\u201398.","journal-title":"Cell"},{"key":"1370_CR21","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/ng.2367","volume":"44","author":"C-L Cheung","year":"2012","unstructured":"Cheung C-L, Lau K-S, Ho AYY, Lee K-K, Tiu S-C, Lau EYF, et al. Genome-wide association study identifies a susceptibility locus for thyrotoxic periodic paralysis at 17q24.3. Nat Genet. 2012;44:1026\u20139.","journal-title":"Nat Genet"},{"key":"1370_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/jhg.2012.20","volume":"57","author":"W Jongjaroenprasert","year":"2012","unstructured":"Jongjaroenprasert W, Phusantisampan T, Mahasirimongkol S, Mushiroda T, Hirankarn N, Snabboon T, et al. A genome-wide association study identifies novel susceptibility genetic variation for thyrotoxic hypokalemic periodic paralysis. J Hum Genet. 2012;57:301\u20134.","journal-title":"J Hum Genet"},{"key":"1370_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cca.2012.08.004","volume":"414","author":"P-Y Chu","year":"2012","unstructured":"Chu P-Y, Cheng C-J, Tseng M-H, Yang S-S, Chen H-C, Lin S-H. Genetic variant rs623011 (17q24.3) associates with non-familial thyrotoxic and sporadic hypokalemic paralysis. Clin Chim Acta. 2012;414:105\u20138.","journal-title":"Clin Chim Acta"},{"key":"1370_CR24","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1212\/WNL.0000000000002524","volume":"86","author":"I-W Song","year":"2016","unstructured":"Song I-W, Sung C-C, Chen C-H, Cheng C-J, Yang S-S, Chou Y-C, et al. Novel susceptibility gene for nonfamilial hypokalemic periodic paralysis. Neurology. 2016;86:1190\u20138.","journal-title":"Neurology"},{"key":"1370_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1210\/js.2017-00015","volume":"1","author":"MCC Melo","year":"2017","unstructured":"Melo MCC, de Souza JS, Kizys MML, Vidi AC, Dorta HS, Kunii IS, et al. Novel lincRNA Susceptibility Gene and Its Role in Etiopathogenesis of Thyrotoxic Periodic Paralysis. J Endocr Soc. 2017;1:809\u201315.","journal-title":"J Endocr Soc"},{"key":"1370_CR26","doi-asserted-by":"crossref","unstructured":"Jeng CJ, Fu SJ, You CY, Peng YJ, Hsiao CT, Chen TY, et al. Defective gating and proteostasis of human ClC-1 chloride channel: molecular pathophysiology of myotonia congenita. Front Neurol. 2020;11:76.","DOI":"10.3389\/fneur.2020.00076"},{"key":"1370_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/164_2017_52","volume":"246","author":"SC Cannon","year":"2018","unstructured":"Cannon SC. Sodium channelopathies of skeletal muscle. Handb Exp Pharm. 2018;246:309\u201330.","journal-title":"Handb Exp Pharm"},{"key":"1370_CR28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nature05598","volume":"446","author":"S Sokolov","year":"2007","unstructured":"Sokolov S, Scheuer T, Catterall WA. Gating pore current in an inherited ion channelopathy. Nature. 2007;446:76\u20138.","journal-title":"Nature"},{"key":"1370_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1085\/jgp.200709755","volume":"130","author":"AF Struyk","year":"2007","unstructured":"Struyk AF, Cannon SC. A Na+ channel mutation linked to hypokalemic periodic paralysis exposes a proton-selective gating pore. J Gen Physiol. 2007;130:11\u201320.","journal-title":"J Gen Physiol"},{"key":"1370_CR30","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1113\/jphysiol.2010.186874","volume":"588","author":"SC Cannon","year":"2010","unstructured":"Cannon SC. Voltage-sensor mutations in channelopathies of skeletal muscle. J Physiol. 2010;588:1887\u201395.","journal-title":"J Physiol"},{"key":"1370_CR31","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1212\/01.wnl.0000342387.65477.46","volume":"72","author":"E Matthews","year":"2009","unstructured":"Matthews E, Labrum R, Sweeney MG, Sud R, Haworth A, Chinnery PF, et al. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology. 2009;72:1544\u20137.","journal-title":"Neurology"},{"key":"1370_CR32","doi-asserted-by":"crossref","unstructured":"Lacroix JJ, Clark Hyde H, Campos FV, Bezanilla F. Moving gating charges through the gating pore in a Kv channel voltage sensor. Proc Natl Acad Sci USA. 2014;111:E1950\u20139.","DOI":"10.1073\/pnas.1406161111"},{"key":"1370_CR33","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1073\/pnas.1115575109","volume":"109","author":"DL Capes","year":"2012","unstructured":"Capes DL, Arcisio-Miranda M, Jarecki BW, French RJ, Chanda B. Gating transitions in the selectivity filter region of a sodium channel are coupled to the domain IV voltage sensor. Proc Natl Acad Sci USA. 2012;109:2648\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1370_CR34","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41586-018-0120-4","volume":"557","author":"D Jiang","year":"2018","unstructured":"Jiang D, Gamal El-Din TM, Ing C, Lu P, Pom\u00e8s R, Zheng N, et al. Structural basis for gating pore current in periodic paralysi. Nature. 2018;557:590\u20134.","journal-title":"Nature"},{"key":"1370_CR35","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1212\/WNL.0b013e3182886a0e","volume":"80","author":"F Wu","year":"2013","unstructured":"Wu F, Mi W, Cannon SC. Bumetanide prevents transient decreases in muscle force in murine hypokalemic periodic paralysis. Neurology. 2013;80:1110\u20136.","journal-title":"Neurology"},{"key":"1370_CR36","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1093\/brain\/awt280","volume":"136","author":"F Wu","year":"2013","unstructured":"Wu F, Mi W, Cannon SC. Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis. Brain. 2013;136:3766\u201374.","journal-title":"Brain"},{"key":"1370_CR37","doi-asserted-by":"crossref","unstructured":"Elia N, Qui\u00f1onez M, Wu F, Mokhonova E, DiFranco M, Spencer MJ, et al. Potassium-sensitive loss of muscle force in the setting of reduced inward rectifier K+ current: Implications for Andersen-Tawil syndrome. Proc Natl Acad Sci USA. 2025;122:e2418021122.","DOI":"10.1073\/pnas.2418021122"},{"key":"1370_CR38","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1212\/WNL.0b013e31828cf8d0","volume":"80","author":"A Horga","year":"2013","unstructured":"Horga A, Raja Rayan DL, Matthews E, Sud R, Fialho D, Durran SCM, et al. Prevalence study of genetically defined skeletal muscle channelopathies in England. Neurology. 2013;80:1472\u20135.","journal-title":"Neurology"},{"key":"1370_CR39","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.nmd.2023.01.007","volume":"33","author":"V Vivekanandam","year":"2023","unstructured":"Vivekanandam V, Jaibaji R, Sud R, Ellmers R, Skorupinska I, Germaine L, et al. Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing. Neuromuscul Disord. 2023;33:270\u20133.","journal-title":"Neuromuscul Disord"},{"key":"1370_CR40","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.nmd.2018.03.006","volume":"28","author":"BC Stunnenberg","year":"2018","unstructured":"Stunnenberg BC, Raaphorst J, Deenen JCW, Links TP, Wilde AA, Verbove DJ, et al. Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands. Neuromuscul Disord. 2018;28:402\u20137.","journal-title":"Neuromuscul Disord"},{"key":"1370_CR41","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.nmd.2020.12.003","volume":"31","author":"R Brugnoni","year":"2021","unstructured":"Brugnoni R, Maggi L, Canioni E, Verde F, Gallone A, Ariatti A, et al. Next-generation sequencing application to investigate skeletal muscle channelopathies in a large cohort of Italian patients. Neuromuscul Disord. 2021;31:336\u201347.","journal-title":"Neuromuscul Disord"},{"key":"1370_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10048-021-00673-2","volume":"23","author":"R Brugnoni","year":"2022","unstructured":"Brugnoni R, Canioni E, Filosto M, Pini A, Tonin P, Rossi T, et al. Mutations associated with hypokalemic periodic paralysis: from hotspot regions to complete analysis of CACNA1S and SCN4A genes. Neurogenetics. 2022;23:19\u201325.","journal-title":"Neurogenetics"},{"key":"1370_CR43","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.nmd.2020.06.001","volume":"30","author":"R Sasaki","year":"2020","unstructured":"Sasaki R, Nakaza M, Furuta M, Fujino H, Kubota T, Takahashi MP. Mutation spectrum and health status in skeletal muscle channelopathies in Japan. Neuromuscul Disord. 2020;30:546\u201353.","journal-title":"Neuromuscul Disord"},{"key":"1370_CR44","doi-asserted-by":"publisher","first-page":"6406","DOI":"10.1007\/s00415-022-11305-6","volume":"269","author":"JH Yuan","year":"2022","unstructured":"Yuan JH, Higuchi Y, Hashiguchi A, Ando M, Yoshimura A, Nakamura T, et al. Genetic spectrum and founder effect of non-dystrophic myotonia: a Japanese case series study. J Neurol. 2022;269:6406\u201315.","journal-title":"J Neurol"},{"key":"1370_CR45","doi-asserted-by":"crossref","unstructured":"Yuan JH, Higuchi Y, Hashiguchi A, Ando M, Yoshimura A, Nakamura T, et al. Gene panel analysis of 119 index patients with suspected periodic paralysis in Japan. Front Neurol. 2023;14:1078195.","DOI":"10.3389\/fneur.2023.1078195"},{"key":"1370_CR46","doi-asserted-by":"crossref","unstructured":"Vacchiano V, Brugnoni R, Campanale C, Imbrici P, Dinoi G, Canioni E, et al. Coexistence of SCN4A and CLCN1 mutations in a family with atypical myotonic features: a clinical and functional study. Exp Neurol. 2023;362:114342.","DOI":"10.1016\/j.expneurol.2023.114342"},{"key":"1370_CR47","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jns.2016.08.030","volume":"369","author":"H Kato","year":"2016","unstructured":"Kato H, Kokunai Y, Dalle C, Kubota T, Madokoro Y, Yuasa H, et al. A case of non-dystrophic myotonia with concomitant mutations in the SCN4A and CLCN1 genes. J Neurol Sci. 2016;369:254\u20138.","journal-title":"J Neurol Sci"},{"key":"1370_CR48","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ana.20241","volume":"56","author":"E Fournier","year":"2004","unstructured":"Fournier E, Arzel M, Sternberg D, Vicart S, Laforet P, Eymard B, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol. 2004;56:650\u201361.","journal-title":"Ann Neurol"},{"key":"1370_CR49","doi-asserted-by":"publisher","first-page":"7377","DOI":"10.1073\/pnas.1230273100","volume":"100","author":"A Tsujino","year":"2003","unstructured":"Tsujino A, Maertens C, Ohno K, Shen X-M, Fukuda T, Harper CM, et al. Myasthenic syndrome caused by mutation of the SCN4A sodium channel. Proc Natl Acad Sci USA. 2003;100:7377\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1370_CR50","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1212\/WNL.0000000000002264","volume":"86","author":"K Habbout","year":"2016","unstructured":"Habbout K, Poulin H, Rivier F, Giuliano S, Sternberg D, Fontaine B, et al. A recessive Nav1.4 mutation underlies congenital myasthenic syndrome with periodic paralysis. Neurology. 2016;86:161\u20139.","journal-title":"Neurology"},{"key":"1370_CR51","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.24389","volume":"77","author":"WD Arnold","year":"2015","unstructured":"Arnold WD, Feldman DH, Ramirez S, He L, Kassar D, Quick A, et al. Defective fast inactivation recovery of Nav1.4 in congenital myasthenic syndrome. Ann Neurol. 2015;77:840\u201350.","journal-title":"Ann Neurol"},{"key":"1370_CR52","doi-asserted-by":"crossref","unstructured":"Elia N, Palmio J, Casta\u00f1eda MS, Shieh PB, Quinonez M, Suominen T, et al. Myasthenic congenital myopathy from recessive mutations at a single residue in Nav1.4. Neurology. 2019;92::e1405\u201315.","DOI":"10.1212\/WNL.0000000000007185"},{"key":"1370_CR53","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/brain\/awv352","volume":"139","author":"IT Zaharieva","year":"2016","unstructured":"Zaharieva IT, Thor MG, Oates EC, Van Karnebeek C, Hendson G, Blom E, et al. Loss-of-function mutations in SCN4A cause severe foetal hypokinesia or \u201cclassical\u201d congenital myopathy. Brain. 2016;139:674\u201391.","journal-title":"Brain"},{"key":"1370_CR54","doi-asserted-by":"crossref","unstructured":"Hadjipanteli A, Theodosiou A, Papaevripidou I, Evangelidou P, Alexandrou A, Salameh N, et al. Sodium channel gene variants in fetuses with abnormal sonographic findings: expanding the prenatal phenotypic spectrum of sodium channelopathies. Genes. 2024;15:119.","DOI":"10.3390\/genes15010119"},{"key":"1370_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s10038-024-01284-z","volume":"70","author":"T Kubota","year":"2025","unstructured":"Kubota T, Nagata M, Takagi K, Ishihara Y, Kojima K, Uchikura Y, et al. Hydrops fetalis due to loss of function of hNav1.4 channel via compound heterozygous variants. J Hum Genet. 2025;70:3\u20138.","journal-title":"J Hum Genet"},{"key":"1370_CR56","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/brain\/aww070","volume":"139","author":"F Wu","year":"2016","unstructured":"Wu F, Mi W, Fu Y, Struyk A, Cannon SC. Mice with an NaV1.4 sodium channel null allele have latent myasthenia, without susceptibility to periodic paralysis. Brain. 2016;139:1688\u201399.","journal-title":"Brain"},{"key":"1370_CR57","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1212\/01.wnl.0000436067.43384.0b","volume":"81","author":"K Aur\u00e9","year":"2013","unstructured":"Aur\u00e9 K, Dubourg O, Jardel C, Clarysse L, Sternberg D, Fournier E, et al. Episodic weakness due to mitochondrial DNA MT-ATP6\/8 mutations. Neurology. 2013;81:1810\u20138.","journal-title":"Neurology"},{"key":"1370_CR58","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1212\/WNL.0000000000004894","volume":"90","author":"E Matthews","year":"2018","unstructured":"Matthews E, Neuwirth C, Jaffer F, Scalco RS, Fialho D, Parton M, et al. Atypical periodic paralysis and myalgia. Neurology. 2018;90:e412\u20138.","journal-title":"Neurology"},{"key":"1370_CR59","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1093\/brain\/awy283","volume":"141","author":"MS Casta\u00f1eda","year":"2018","unstructured":"Casta\u00f1eda MS, Zanoteli E, Scalco RS, Scaramuzzi V, Caldas VM, Reed UC, et al. A novel ATP1A2 mutation in a patient with hypokalaemic periodic paralysis and CNS symptoms. Brain. 2018;141:3308\u201318.","journal-title":"Brain"},{"key":"1370_CR60","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mus.26622","volume":"60","author":"EK Gustavsson","year":"2019","unstructured":"Gustavsson EK, Follett J, Farrer MJ, Aasly JO. Family with primary periodic paralysis and a mutation in MCM3AP, a gene implicated in mRNA transport. Muscle Nerve. 2019;60:311\u20134.","journal-title":"Muscle Nerve"},{"key":"1370_CR61","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.1007\/s00415-023-11964-z","volume":"270","author":"S Holm-Yildiz","year":"2023","unstructured":"Holm-Yildiz S, Krag T, Witting N, Pedersen BS, Dysgaard T, Sloth L, et al. Hypokalemic periodic paralysis: a 3-year follow-up study. J Neurol. 2023;270:6057\u201363.","journal-title":"J Neurol"},{"key":"1370_CR62","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/humu.21501","volume":"32","author":"T Kubota","year":"2011","unstructured":"Kubota T, Roca X, Kimura T, Kokunai Y, Nishino I, Sakoda S, et al. A mutation in a rare type of intron in a sodium-channel gene results in aberrant splicing and causes myotonia. Hum Mutat. 2011;32:773\u201382.","journal-title":"Hum Mutat"},{"key":"1370_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-29759-7","volume":"13","author":"JJ Pedersen","year":"2023","unstructured":"Pedersen JJ, Stemmerik MG, Jacobsen LN, Skriver SV, Wilms GR, Duno M, et al. Muscle fat replacement and contractility in patients with skeletal muscle sodium channel disorders. Sci Rep. 2023;13:1\u201311.","journal-title":"Sci Rep"},{"key":"1370_CR64","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.nmd.2021.06.010","volume":"31","author":"S Vicart","year":"2021","unstructured":"Vicart S, Franques J, Bouhour F, Magot A, P\u00e9r\u00e9on Y, Sacconi S, et al. Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study. Neuromuscul Disord. 2021;31:1124\u201335.","journal-title":"Neuromuscul Disord"},{"key":"1370_CR65","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S1474-4422(24)00320-X","volume":"23","author":"V Vivekanandam","year":"2024","unstructured":"Vivekanandam V, Skorupinska I, Jayaseelan DL, Matthews E, Barohn RJ, McDermott MP, et al. Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial. Lancet Neurol. 2024;23:1004\u201312.","journal-title":"Lancet Neurol"},{"key":"1370_CR66","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1212\/WNL.0000000000002416","volume":"86","author":"VA Sansone","year":"2016","unstructured":"Sansone VA, Burge J, McDermott MP, Smith PC, Herr B, Tawil R, et al. Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Neurology. 2016;86:1408\u201316.","journal-title":"Neurology"},{"key":"1370_CR67","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/mus.27354","volume":"64","author":"VA Sansone","year":"2021","unstructured":"Sansone VA, Johnson NE, Hanna MG, Ciafaloni E, Statland JM, Shieh PB, et al. Long-term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis. Muscle Nerve. 2021;64:342\u20136.","journal-title":"Muscle Nerve"},{"key":"1370_CR68","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1212\/WNL.31.11.1423","volume":"31","author":"CF Torres","year":"1981","unstructured":"Torres CF, Griggs RC, Moxley RT, Bender AN. Hypokalemic periodic paralysis exacerbated by acetazolamide. Neurology. 1981;31:1423\u20138.","journal-title":"Neurology"},{"key":"1370_CR69","doi-asserted-by":"crossref","unstructured":"Qui\u00f1onez M, Difranco M, Wu F, Cannon SC, Drive CEY. Retigabine suppresses loss of force in mouse models of hypokalaemic periodic paralysis. Brain. 2023;146:1554\u201360.","DOI":"10.1093\/brain\/awac441"},{"key":"1370_CR70","doi-asserted-by":"crossref","unstructured":"Kubota T, Takahashi S, Yamamoto R, Sato R, Miyanooto A, Yamamoto R, et al. Optical measurement of gating pore currents in hypokalemic periodic paralysis model cells. Dis Model Mech. 2023;16:dmm049704.","DOI":"10.1242\/dmm.049704"}],"container-title":["Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s10038-025-01370-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s10038-025-01370-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s10038-025-01370-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:21:22Z","timestamp":1757344882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s10038-025-01370-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":70,"alternative-id":["1370"],"URL":"https:\/\/doi.org\/10.1038\/s10038-025-01370-w","relation":{},"ISSN":["1434-5161","1435-232X"],"issn-type":[{"value":"1434-5161","type":"print"},{"value":"1435-232X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TK is currently receiving a grant from Japan Agency for Medical Research and Development (AMED) and Japan Society for the Promotion of Science (JSPS) KAKANHI and has received honoraria for lectures from Argenx, Alexion Pharmaceuticals and UCB Pharma. MPT is currently receiving a grant from AMED, the Ministry of Health, Labour and Welfare of Japan, the National Center for Neurology and Psychiatry Japan and Japan Blood Products Organization and has received honoraria from Alexion, Alnylam, argenx, Dyne Therapeutics, Japan Clinical Research Operations, LSI Medience, Nippon Shinyaku, Nobel Pharma, Ono Pharmaceutical and UCB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}